Oscar Health, Inc. (OSCR)
NYSE: OSCR · Real-Time Price · USD
13.42
-0.29 (-2.12%)
At close: Feb 13, 2026, 4:00 PM EST
13.55
+0.13 (0.94%)
After-hours: Feb 13, 2026, 7:59 PM EST
Oscar Health Stock Forecast
Stock Price Forecast
The 7 analysts that cover Oscar Health stock have a consensus rating of "Hold" and an average price target of $17, which forecasts a 26.68% increase in the stock price over the next year. The lowest target is $11 and the highest is $25.
Price Target: $17 (+26.68%)
Analyst Consensus: Hold
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Oscar Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 2 | 3 | 2 | 3 | 5 | 5 |
| Sell | 4 | 4 | 3 | 2 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 7 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Sell → Hold Upgrades $12 → $17 | Strong Sell → Hold | Upgrades | $12 → $17 | +26.68% | Jan 9, 2026 |
| Barclays | Barclays | Sell → Hold Upgrades $13 → $18 | Sell → Hold | Upgrades | $13 → $18 | +34.13% | Jan 5, 2026 |
| Stephens & Co. | Stephens & Co. | Hold Initiates $17 | Hold | Initiates | $17 | +26.68% | Dec 11, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $13 → $25 | Hold → Buy | Upgrades | $13 → $25 | +86.29% | Nov 26, 2025 |
| Wells Fargo | Wells Fargo | Sell Maintains $14 → $11 | Sell | Maintains | $14 → $11 | -18.03% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
12.82B
from 11.70B
Increased by 9.53%
Revenue Next Year
14.69B
from 12.82B
Increased by 14.64%
EPS This Year
-0.03
from -1.69
EPS Next Year
1.01
from -0.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 15.7B | 17.5B | |
| Avg | 12.8B | 14.7B | |
| Low | 10.3B | 10.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 34.5% | 36.6% | |
| Avg | 9.5% | 14.6% | |
| Low | -12.1% | -17.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.46 | 1.63 | |
| Avg | -0.03 | 1.01 | |
| Low | -0.92 | 0.55 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.